NCT00956332View on ClinicalTrials.gov

Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

May 31, 2026

Conditions
Peripheral Arterial DiseasePeripheral Vascular DiseaseCritical Limb Ischemia
Interventions
BIOLOGICAL

MultiGeneAngio

Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

BIOLOGICAL

MultiGeneAngio

Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

Trial Locations (7)

31096

Rambam Medical Center, Haifa

52621

Chaim Sheba Medical Center, Tel Litwinsky

76100

Kaplan Medical Center, Rehovot

78278

Barzilai Medical Center, Ashkelon

84101

Soroka Medical Center, Beersheba

91031

Shaare Zedek Medical Center, Jerusalem

91120

Hadassah University Hospital, Ein Kerem, Jerusalem

All Listed Sponsors
lead

MultiGene Vascular Systems Ltd.

INDUSTRY

NCT00956332 - Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia | Biotech Hunter | Biotech Hunter